RxDoctor Payments Data

Craig Stauffer, MD

Urology · Monterey, CANPI 1689932709

Payments from drug & device makers

$4,031in general payments, 2019–2025

Across 50 payments — averaging $80.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$1K
  • Boston Scientific$1K
  • EDAP Technomed Inc$894
  • Valencia Technologies Corporation$580
  • Medtronic$135
  • Astellas Pharma US Inc$52
  • plus $85 from 3 others

What the payments were for

  • Travel & lodging$2,10852%
  • Food & beverage$1,87146%
  • Education$521%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,031 in reported general payments places this provider in the 55th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$397,794
Medicare patients
1,068
Services billed
4,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron38$43,466
GemtesaVibegron11$9,064
Tamsulosin Hcl234$3,366
Finasteride169$2,294
Trospium Chloride ErTrospium Chloride13$2,198
Oxybutynin Chloride ErOxybutynin Chloride85$1,763
Potassium Citrate ErPotassium Citrate15$1,488
Alfuzosin Hcl ErAlfuzosin Hcl13$232
Tadalafil12$216
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$198
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$121
Levofloxacin42$116
Cephalexin24$74
Tramadol Hcl40$66
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$52$43,46638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,324 urology providers in California.

Other urology in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →